A clear brand logo can make it easier to verify official resources
Patients should contact their healthcare provider if they experience any of the following: Seek emergency medical care immediately for: Signs of severe allergic reaction (anaphylaxis), including difficulty breathing, severe rash, or swelling of the face, lips, or throat Severe, persistent abdominal pain that may radiate to your back, with or without vomiting, which could indicate pancreatitis Symptoms of thyroid tumors, such as a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath Contact your provider within 24-48 hours for: Persistent or worsening injection site reactions beyond mild, transient redness New or unusual skin rashes, blistering, or skin changes Signs of gallbladder problems, including upper right abdominal pain, fever, yellowing of skin or eyes, or clay-colored stools Symptoms of kidney problems, such as decreased urination, swelling in legs or feet, or unusual fatigue Recurrent hypoglycemia (blood glucose below 70 mg/dL), especially if taking insulin or sulfonylureas concurrently New or worsening vision changes, particularly if you have a history of diabetic retinopathy Severe, persistent vomiting or diarrhea leading to dehydration If you become pregnant while taking tirzepatide, contact your healthcare provider immediately
This is how you can introduce your patient to GLP-1 therapy, integrating it thoughtfully into a comprehensive weight management plan for safe and sustainable results
Semaglutide is currently facing a shortage and limited access, and Tirzepatide might follow suit as it becomes more prevalent
The Medicines and Healthcare products Regulatory Agency has not approved it for any clinical use, and it cannot lawfully be marketed for human consumption, sold as a supplement, or prescribed on the NHS
